CLS Americas and URN Announce First Patient Treated in Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer”
CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced the first patient has been safely treated in its recently announced 20-patient, Phase I clinical study titled, “Targeted MRI/US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.” The study utilizes CLS’s TRANBERG® Thermal Therapy System in combination with the Focalyx® Fusion medical device for treatment planning, image fusion, and real-time image guidance during the high-